During the last session, Stoke Therapeutics Inc (NASDAQ:STOK)’s traded shares were 0.87 million, with the beta value of the company hitting 1.10. At the end of the trading day, the stock’s price was $11.58, reflecting an intraday gain of 0.09% or $0.01. The 52-week high for the STOK share is $16.15, that puts it down -39.46 from that peak though still a striking 53.8% gain since the share price plummeted to a 52-week low of $5.35. The company’s market capitalization is $632.24M, and the average intraday trading volume over the past 10 days was 0.51 million shares, and the average trade volume was 790.05K shares over the past three months.

Stoke Therapeutics Inc (STOK) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.20. STOK has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it.

Stoke Therapeutics Inc (NASDAQ:STOK) trade information

Stoke Therapeutics Inc (STOK) registered a 0.09% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.09% in intraday trading to $11.58, hitting a weekly high. The stock’s 5-day price performance is -2.03%, and it has moved by 15.22% in 30 days. Based on these gigs, the overall price performance for the year is -25.77%. The short interest in Stoke Therapeutics Inc (NASDAQ:STOK) is 12.03 million shares and it means that shorts have 17.79 day(s) to cover.

The consensus price target of analysts on Wall Street is $22, which implies an increase of 47.36% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $58 respectively. As a result, STOK is trading at a discount of -400.86% off the target high and -55.44% off the low.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 1.74%. While earnings are projected to return 100.42% in 2025, the next five years will return -14.28% per annum.

STOK Dividends

Stoke Therapeutics Inc is due to release its next quarterly earnings on 2025-May-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

The next largest institutional holding, with 5.41 million shares, is of BLACKROCK INC.’s that is approximately 9.6998% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $73.08 million.